Two genetic pathologies have been identified for CPVT, the autosomal dominant form associated with mutations of the genes encoding ryanodine receptor 2 (RYR2) and involving mutations encoding cardiac calsequestrin (CASQ2) (Lahat et al., 2001; Priori et al., 2001). Here, CASQ2 is linked to catecholaminergic polymorphic ventricular tachycardia.